Theriva™ Biologics anuncia que ha obtenido la autorización reglamentaria para llevar a cabo el ensayo clínico de Fase IIa VIRAGE2, destinado a evaluar una administración más frecuente de VCN-01 (zabilugene almadenorepvec) en pacientes en tratamiento de primera línea con adenocarcinoma pancreático ductal metastásico

Phase 2VCN-01Positive

AI Analysis

Summary

Theriva Biologics obtained regulatory authorization to conduct the Phase IIa VIRAGE2 trial evaluating more frequent dosing of VCN-01 in patients with metastatic ductal pancreatic adenocarcinoma, designed to optimize dosing regimen for a future Phase III pivotal trial.

Clinical Trial Data

Phase

Phase IIa

Outcome Details

Regulatory authorization obtained to conduct Phase IIa VIRAGE2 trial

Importance:6/10

Sentiment:

0.60

regulatory_approvalclinical_trialoncologypancreatic_cancerdose_optimization

Related Companies

$TOVX

Read the original article

Published by GlobeNewswire Clinical Studies on July 7, 2026 3:16 PM

Read Original